Please assess the completion status of the following clinical trial:

Trial Title: Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* 1. Patient successfully completed the Phase 1b/2a study with WVE-120101, WVE-HDSNP1-001.~Key Exclusion Criteria:~* 1. Received an investigational drug other than WVE-120101, including an investigational oligonucleotide, within the past 1 year or 5 half-lives of the drug, whichever is longer.~* 2. Inability to undergo brain MRI (with or without sedation).~* 3. Clinically significant medical finding on the physical examination other than HD that, in the judgment of the Investigator, will make the patient unsuitable for participation in and/or completion of the study procedures.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- WVE-120101 (Dose A) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).